Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Current Deferred Revenue (2016 - 2019)

Historic Current Deferred Revenue for Avadel Pharmaceuticals (AVDL) over the last 11 years, with Q1 2019 value amounting to $115000.0.

  • Avadel Pharmaceuticals' Current Deferred Revenue changed N/A to $115000.0 in Q1 2019 from the same period last year, while for Mar 2019 it was $115000.0, marking a year-over-year change of. This contributed to the annual value of $114000.0 for FY2018, which is 9431.99% down from last year.
  • Latest data reveals that Avadel Pharmaceuticals reported Current Deferred Revenue of $115000.0 as of Q1 2019.
  • Avadel Pharmaceuticals' 5-year Current Deferred Revenue high stood at $5.1 million for Q4 2015, and its period low was $21000.0 during Q2 2015.
  • For the 5-year period, Avadel Pharmaceuticals' Current Deferred Revenue averaged around $2.2 million, with its median value being $2.1 million (2015).
  • As far as peak fluctuations go, Avadel Pharmaceuticals' Current Deferred Revenue skyrocketed by 1809047.62% in 2016, and later plummeted by 9431.99% in 2018.
  • Over the past 5 years, Avadel Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $5.1 million in 2015, then tumbled by 56.59% to $2.2 million in 2016, then decreased by 9.72% to $2.0 million in 2017, then tumbled by 94.32% to $114000.0 in 2018, then rose by 0.88% to $115000.0 in 2019.
  • Its Current Deferred Revenue stands at $115000.0 for Q1 2019, versus $114000.0 for Q4 2018 and $1.7 million for Q3 2018.